Triptolide targets PPP2CA/ITGA5 axis to suppress lactate-driven ovarian cancer progression

Abstract Background Triptolide, the active compound of Tripterygium wilfordii, exhibits broad anti-tumor activity. This study explores PPP2CA dysregulation in ovarian cancer (OC) progression via lactate production and evaluates Triptolide’s potential to regulate this process. Methods We used patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Ling Ding, Wutao Chen, Cenxin Luo, Nathaniel Weygant, Yi Lai, Dan Ru, Hengan Liu, You Wang, He Li
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Chinese Medicine
Subjects:
Online Access:https://doi.org/10.1186/s13020-025-01174-2
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Triptolide, the active compound of Tripterygium wilfordii, exhibits broad anti-tumor activity. This study explores PPP2CA dysregulation in ovarian cancer (OC) progression via lactate production and evaluates Triptolide’s potential to regulate this process. Methods We used patient-derived xenograft (PDX) models, cell proliferation, and migration assays to assess lactate’s impact on OC progression. CRISPR-Cas9 was applied to knock out PPP2CA, examining its effect on lactate production and tumor progression. RNA-seq analyzed transcriptomic changes post-PPP2CA knockout. The PPP2CA-ITGA5 axis was validated using xenografts, immunofluorescence, immunohistochemistry staining and western blot. Exosome isolation and co-culture experiments with tumor cells and human peritoneal mesothelial cells (HPMCs) investigated ITGA5’s role in migration. Finally, patient-derived organoids, xenograft tumor model, and lactate assays assessed Triptolide’s reversal effect on PPP2CA dysregulation-driven OC progression. Results We found that PPP2CA dysregulation significantly promotes OC proliferation, migration, and tumorigenesis by enhancing YAP nuclear translocation and upregulating ITGA5/ITGB1. PPP2CA dysregulation led to ITGA5 upregulation, where ITGA5, as part of the integrin α5β1 heterodimer, plays a key role in driving OC migration. Exosomal ITGA5 facilitates OC metastasis to the HPMCs. Triptolide effectively inhibited patient-derived organoid growth and reduced lactate production in OC cells. By suppressing ITGA5, Triptolide reversed cancer progression and restored tumor-suppressive effects in a PPP2CA-knockout xenograft model. Conclusion Our study reveals that Triptolide effectively inhibits OC progression by targeting the PPP2CA-ITGA5 axis, mitigating lactate-driven metabolic reprogramming. Graphic Abstract
ISSN:1749-8546